Hologic Announces Third Quarter Fiscal 2008 Operati...(emand for its products and productsunder...),Health

Date:7/30/2008

emand for its products, and products under development, and to develop strategies to address its markets successfully; the early stage of market development for certain of the Company's products; expenses and uncertainties relating to litigation; risks related to the use and protection of intellectual property; technical innovations that could render products marketed or under development by the Company obsolete; competition; general worldwide economic conditions and related uncertainties; future legislative, regulatory, or tax changes as well as other economic, business and/or competitive factors; and the effect of exchange rate fluctuations on international operations. The risks included above are not exhaustive.

Other factors that could adversely affect the Company's business and prospects are described in the Company's filings with the Securities and Exchange Commission. The Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in the Company's expectations or any change in events, conditions or circumstances on which any such statement is based.

HOLOGIC, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)

(In thousands)

ASSETS

June 28, 2008 September 29, 2007

CURRENT ASSETS:

Cash and cash equivalents $119,863 $100,403

Accounts receivable, net 313,384 152,743

Inventories 178,500 105,289

Deferred income tax asset 32,709 29,356

Prepaid expenses and other current

assets 50,984 11,389

Total cu
'/>"/>

SOURCE Hologic, Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
Related medicine news :

1. Psychological downside to strike action
2. Psychological and Social Issues Associated With Tooth Loss
3. Psychological and social issues associated with tooth loss
4. Hologic, Inc. Announces Grant of Early Termination of Antitrust Waiting Period for Third Wave Technologies, Inc. Tender Offer
5. Hologic to Present at the Jefferies 2nd Annual Healthcare Conference
6. Hologic to Acquire Third Wave Technologies
7. Metformin increases pathologic complete response rates in breast cancer patients with diabetes
8. Hologic to Present at NASDAQs 21st Investor Program in London
9. Hologic Announces Organizational Change
10. Can pathological techniques help identify primary colorectal signet ring cell carcinoma?
11. Electric shocks can cause neurologic and neuropsychological symptoms